Edition:
United States

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

3.97EUR
21 Nov 2017
Change (% chg)

-- (--)
Prev Close
€3.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
115,885
52-wk High
€5.78
52-wk Low
€3.63

Chart for

About

MDxHealth SA is a Belgium-based multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis... (more)

Overall

Beta: 0.94
Market Cap(Mil.): €201.44
Shares Outstanding(Mil.): 49.95
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.64 15.49
EPS (TTM): -- -- --
ROI: -- -10.01 11.95
ROE: -- -35.77 15.94

BRIEF-MDxHealth teams up with Ferrer for distribution of its prostate cancer test SelectMDx in Spain

* REG-MDXHEALTH TEAMS UP WITH PHARMACEUTICAL COMPANY FERRER FOR DISTRIBUTION OF ITS PROSTATE CANCER TEST SELECTMDX IN SPAIN

Nov 20 2017

BRIEF-MDX Pcl posts ‍qtrly net profit of 86.1 mln baht

* ‍Qtrly net profit 86.1 million baht versus 19.8 million baht Source text for Eikon: Further company coverage:

Nov 14 2017

BRIEF-MDxHealth 9M total revenue at 30.5 million dollars

* 9M (NOT Q3) NET LOSS $‍​7.4 MILLION VERSUS LOSS OF $10.3 MILLION YEAR AGO

Nov 02 2017

BRIEF-MDxhealth enters distribution agreement with Unilabs for SelectMDx

* ‍MDXHEALTH ENTERS INTO DISTRIBUTION AGREEMENT WITH UNILABS FOR SELECTMDX FOR PROSTATE CANCER ​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 30 2017

BRIEF-MDxHealth opens new laboratory in the Netherlands

* MDXHEALTH OPENS NEW SERVICE AND RESEARCH LABORATORY IN THE NETHERLANDS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 05 2017

BRIEF-MDxHealth appoints Michael K. Brawer as Chief Medical Officer‍​

* ANNOUNCES APPOINTMENT OF MICHAEL K. BRAWER, MD AS CHIEF MEDICAL OFFICER‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 06 2017

BRIEF-MDxHealth H1 EBITDA rises to 1.4 million dollars

* H1 ‍TOTAL REVENUE OF $24.3 MILLION, UP 87% FROM $12.9 MILLION IN 2016​

Aug 31 2017

BRIEF-MDxHealth announces ConfirmMDx study provides further validation of epigenetic risk profile

* REG-CONFIRMMDX STUDY PROVIDES FURTHER VALIDATION OF EPIGENETIC RISK PROFILE

Aug 10 2017

REFILE-BRIEF-MDxHealth signs service agreement with Kaiser Southern California Permanente Medical Group

* REG-MDXHEALTH ANNOUNCES SERVICE AGREEMENT WITH KAISER SOUTHERN CALIFORNIA PERMANENTE MEDICAL GROUP

Aug 08 2017

BRIEF-Mdxhealth announced Mvz Dr. Stein & Kollegen to offer the SelectMDx for prostate cancer test

* MVZ DR. STEIN & KOLLEGEN FIRST GERMAN MEDICAL LABORATORY TO OFFER THE SELECTMDX FOR PROSTATE CANCER TEST

Jul 31 2017

Earnings vs. Estimates